Trial Profile

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levodopa/carbidopa (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms ELEVATE-PD
Sponsors IMPAX Laboratories

Most Recent Events

05 Jun 2026 Results presented in the Amneal Pharmaceuticals Media Release
05 Jun 2026 According to a Amneal Pharmaceuticals media release, with enrollment in ELEVATE-PD now complete and patients continuing through the 12-month follow-up period, Amneal will present longer-term outcomes and patient-reported results throughout 2026
05 Jun 2026 Status changed from recruiting to active, no longer recruiting as per Amneal Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com